Haven't confirmed any of this yet, but just heard rumors of change, and another 'superoffice' restructuring at FDA. Apparently, within the new framework, the Office of Generic Drugs will become a "superoffice", OPS will be no more, while OMPQ, ONDQA and OBP will report to OPQ. The Office of Compliance will continue to take on more of an enforcement role.
Seems fitting that OGD should have a much more prominent place, given that most prescriptions being written and dispensed in the U.S. today are generics.
Again, more on this soon.